Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia

Journal of Pain and Symptom Management

Volumn 14, Issue 1, 1997, Pages 7-14

  Beal, Jeffrey E ^a   Olson, Richard ^b   Lefkowitz, Lewis ^c   Laubenstein, Linda ^d   Bellman, Paul ^e   Yangco, Bienvenido ^f   Morales, Javier O ^g   Murphy, Robert ^j   Powderly, William ^h   Plasse, Terry F ^j   Mosdell, Kristen W ⁱ   Shepard, Kirk V ^i,j  

^a St John's Hospital   (United States)

^b Oaklawn Physicians Group   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e Community Research Initiative ^*  (United States)

^f INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^g Ashford Presbyt Community Hospital   (Puerto Rico)

^h WASHINGTON UNIVERSITY   (United States)

ⁱ Roxane Laboratories Inc   (United States)

^j NONE

more..

Author keywords

Acquired immunodeficiency syndrome; AIDS; Anorexia; Cachexia; Dronabinol; HIV; Human immunodeficiency virus

Indexed keywords

DRONABINOL;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANOREXIA; APPETITE; ARTICLE; CACHEXIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MAJOR CLINICAL STUDY; MALE; QUALITY OF LIFE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANOREXIA; APPETITE; APPETITE STIMULANTS; BODY WEIGHT; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; TETRAHYDROCANNABINOL;

EID: 8544278893     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(97)00038-9     Document Type: Article

References (22)

1. Centers for Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 1987;36(suppl 1):1S-15S.
2. Centers for Disease Control. HIV/AIDS Surveill Rep 1992;April:1-18.
3. Coodley GO, Loveless MO, Merrill TM. The HIV wasting syndrome: a review. J Acquir Immune Defic Syndr 1994;7:681-694.
4. Bell SJ, Mascioli EA, Forse RA, Bistrian BR. Nutrition support and the human immunodeficiency virus (HIV). Parasitology 1993;107:S53-S67.
5. Gorbach SL, Knox TA, Roubenoff R. Interactions between nutrition and infection with human immunodeficiency virus. Nutr Rev 1993;51:226-234.
6. Gorter R. Management of anorexia-cachexia associated with cancer and HIV infection. Oncology 1991;5(suppl):13-17.
7. Schwenk A, Bürger B, Wessel D, et al. Clinical risk factors for malnutrition in HIV-1-infected patients. AIDS 1993;7:1213-1219.
8. Grunfeld C, Kotler DP. Wasting in the acquired immunodeficiency syndrome. Semin Liver Dis 1992;12:175-187.
9. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995;333:83-88.
10. Kotler DP, Tierney AR, Wang J, Pierson RN. Magnitude of body-cell-mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 1989;50:444-447.
11. Chlebowski RT, Grosvenor MB, Bernhard NH, Morales LS, Bulcavage LM. Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 1989;84:1288-1293.
12. Palenicek JP, Graham NMH, He YD, et al. Weight loss prior to clinical AIDS as a predictor of survival. J Acquir Immune Defic Syndr 1995;10: 366-373.
13. Gorter R, Seefried M, Volberding P. Dronabinol effects on weight in patients with HIV infection. AIDS 1992;6:127-138.
14. Plasse TF, Gorter RW, Krasnow SH, Lane M, Shepard KV, Wadleigh RG. Recent clinical experience with dronabinol. Pharmacol Biochem Behav 1991;40:695-700.
15. Struwe M, Kaempfer SH, Geiger CJ, et al. Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993;27:827-831.
16. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage 1995;10:89-97.
17. Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994;121:393-399.
18. Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994;121:400-408.
19. Wagner G, Rabkin JG, Rabkin R. Illness stage, concurrent medications, and other correlates of low testosterone in men with HIV illness. J Acquir Immune Defic Syndr 1995;8:204-207.
20. Engelson ES, Pi-Sunyer FX, Kotler DP. Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS [Letter]. AIDS 1995;9:1107-1108.
21. Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with AIDS. Ann Intern Med 1995;122:843-845.
22. Del Valle LG, Ambrosio AH, Hernandez PM, Diaz BG, Caballero EJ. Hyperglycemia induced by megestrol acetate in a patient with AIDS. Ann Pharmacother 1996;30:1113-1114.